Net sales by business area

  3 months ending   12 months ending
SEKm 31 Dec 21 % 31 Dec 20   31 Dec 21 % 31 Dec 20
Labtech 1,089 -15 1,283   4,373 21 3,619
Medtech 1,043 132 449   3,625 118 1,659
Group items -1   -1   -5   -5
AddLife Group 2,131 23 1,731   7,993 52 5,273

EBITA and EBITA-margin by business area and operating profit for the group

  3 months ending 12 months ending
SEKm 31 Dec 21 % 31 Dec 20 % 31 Dec 21 % 31 Dec 20 %
Labtech 227 20.8 273 21.3 977 22.3 622 17.2
Medtech 108 10.4 49 11.0 310 8.6 196 11.8
Parent Company and Group items -6   -6   -14   -16  
EBITA 329 15.5 316 18.2 1,273 15.9 802 15.2
Depreciation intangible assets -84   -38   -277   -130  
Operating profit 245 11.5 278 16.1 996 12.5 672 12.8
Finance income and expenses -22   -2   -69   -13  
Profit after financial items 223   276   927   659  

 

Net sales by revenue type

  3 months ending 12 months ending
SEKm 31 Dec 21 31 Dec 20 31 Dec 21 31 Dec 20
Products        
Labtech 840 912 3,518 2,662
Medtech 864 412 3,048 1,477
Group items -1 -1 -5 -5
The Group 1,703 1,323 6,561 4,134
Instruments        
Labtech 200 317 673 756
Medtech 101 35 346 180
The Group 301 352 1,019 936
Service        
Labtech 49 54 182 201
Medtech 78 2 231 2
The Group 127 56 413 203
Total 2,131 1,731 7,993 5,273

As of April 1, 2021, the Biomedica companies are included as a whole in the business area Labtech. Previously, the Biomedica companies were distributed with 60 percent in Labtech and 40 percent in Medtech. All key financial indicators have been recalculated in accordance with the new breakdown.

Latest updated: 2/3/2022 4:51:51 PM by jamilah.wass@add.life